Skip to main content
Premium Trial:

Request an Annual Quote

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.